Biography
Prior to CosmosID, Mr. Dadlani served as a partner at Applied Value Group, a management consulting and investment firm, and was co-founder and CEO at Rasa Industries, Ltd., a leading beverage manufacturing company. Mr. Dadlani has substantial experience in strategy, M&A, supply chain management, product development, marketing and business development. Mr. Dadlani received his Bachelor’s and Master’s degrees in Biological Engineering from Cornell University. Services offered by CosmosID’s CLIA and GLP certified laboratory cover the entire workflow from study design to sample collection, extraction, library preparation, sequencing, data analysis and publication support. CosmosID’s cloud-based metagenomics application offers user-friendly access to the largest curated databases for microbial genomics, antimicrobial resistance and virulence data and has been independently validated to return metagenomic analyses at strain level resolution with industry-leading sensitivity and precision.
Track Chair:
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.